Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC41 Tablet in Adult NASH Patients (Phase II, Randomized, Double-blind, Placebo-controlled)
CTR20221529Phase 2Completed
- Sponsor
- Gannex Pharma Co., Ltd.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing ASC41 arm with Placebo arm (2 arms). Started Jun 2022; status: completed.
02
Drugs
ASC-41
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20221529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221529.